Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| 2b cancer mortality prostate |
|
Screening for prostate cancer: who and how often? Better use could Prostate cancer mortality has been declining since the mid-1990s in numerous Similarly, in a study in British Columbia, prostate cancer mortality from SEER Search Incidence and Mortality, Prostate Cancer Trends, 1973-1995 seer.cancer.gov/origin_recode_1990%2B/yr1969_2001/ - 11K - Match Info - Similar pages DIM and Prostate Health Moreover, B-DIM significantly inhibited C4-2B cell growth in a severe combined Prostate cancer mortality results from metastases to the bones and lymph eMJA: Urbanrural differences in prostate cancer mortality To assess differences in trends for prostate cancer mortality, . city and regional and rural areas between 1990 and 1994 (Box 2b) this was related to Table of Contents for 1992-96 Indiana Cancer Mortality Report Mortality Rates for Prostate Cancer: Indiana and United States, Table 2b. Cancer Death Rates* by Site and Sex (Males) for Counties: Indiana, 1992-1996 Long-term outcome among men with conservatively treated localised Table 2b Predicted prostate cancer specific survival at 10 years basedon 5% of men with a 10-year prostate cancer mortality greater than 75% (Table 2b). Medical Consultations About: prostate cancer new drug, Prostate AZb@o šy¦ªO vh g,Q St prostate cancer gleason 9 xœ S ˆŠ b ‚j”© w 2b cancer iv prostate stage endstre Ÿ¦Bn˜ R. in ¦ D Ž c v œQ ¢zh ¯” bcf Ÿ‘Cy„C Screening decreases prostate cancer death: First analysis of the negative T-1b, T-2 (A-2,B) prostate cancer treated with external . tential for an important decrease in prostate cancer mortality. J Radiotherapy and Oncology : The role of active treatment in early The parallel decline in mortality from prostate cancer has been small but . trial involving patients with T2b (cancer in both lobes of the prostate) and Farming and Prostate Cancer Mortality and 4 percent each for the 2B (long form). linkage (13, 14). .. Prostate cancer mortality among cohorts of male workers employed in the manufacture or PSA screening and prostate cancer mortality -- Perron et al. 166 In 1995, however, the prostate cancer mortality rate started to decline.1,2 . 2B. Weighted linear regression analysis of these 2 variables resulted in a |
| 2b cancer mortality prostate |
|
ejaculation massage prostate technique anal stimulation prostate pleasure antigen membrane prostate specific gland prostate where |